Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy. - Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.

Department of Urology, Saitama Medical Center, Saitama Medical University0 sites5 target enrollmentSeptember 26, 2014

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: urothelial cancer
Sponsor: Department of Urology, Saitama Medical Center, Saitama Medical University
Enrollment: 5
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

September 26, 2014

End Date

March 31, 2017

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Department of Urology, Saitama Medical Center, Saitama Medical University

•Patients 1\) have a treatment history of paclitaxel treatment 2\) have an allergy to albumin 3\) have a heavy infection 4\) have severe complications: interstitial pulmonary fibrosis, gastrointestinal hemorrhage, ileus, uncontrollable diabetes mellitus, cardiovascular disease, etc. 5\) have an uncontrollable pleural, ascites or pericardial effusion. 6\) have an active cancer except urothelial cancer: cancer free duration \< 5 years. 7\) have a brain metastasis with symptoms requiring steroids or anti\-seisure medications 8\) have a history of salvage radiation to primary organ or lymph node metastasis within two weeks. 9\) do not meet the inclusion criteria due to mental disorders or neurological symptoms 10\) have no intention to birth control 11\) disqualified by a doctor in charge